Drug Price Trends for NDC 46122-0752

Average Pharmacy Cost for 46122-0752

Drug Name	NDC	Price/Unit ($)	Unit	Date
GNP DICLOFENAC SODIUM 1% GEL	46122-0752-53	0.06890	GM	2026-03-18
GNP DICLOFENAC SODIUM 1% GEL	46122-0752-37	0.12634	GM	2026-03-18
GNP DICLOFENAC SODIUM 1% GEL	46122-0752-52	0.08983	GM	2026-03-18
GNP DICLOFENAC SODIUM 1% GEL	46122-0752-53	0.06922	GM	2026-02-18
GNP DICLOFENAC SODIUM 1% GEL	46122-0752-37	0.12709	GM	2026-02-18
GNP DICLOFENAC SODIUM 1% GEL	46122-0752-52	0.09149	GM	2026-02-18

Best Wholesale Price for NDC 46122-0752

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 46122-0752

Last updated: February 24, 2026

What is the drug with NDC 46122-0752?

The drug NDC 46122-0752 corresponds to Xyosted (testosterone enanthate, injectable). Xyosted is approved for hormone replacement therapy in adult males with testosterone deficiency.

Market Overview

Therapeutic Area and Indication

• Used for testosterone replacement therapy (TRT).
• Addresses hypogonadism in adult males.
• Market segment includes endocrinologists, urologists, general practitioners, and specialized clinics.

Market Size

• The global testosterone replacement therapy market was valued at approximately USD 1.4 billion in 2021.
• Expected compound annual growth rate (CAGR): 4.8% (2022–2027) [1].

Competitive Landscape

• Key competitors include testosterone gels (e.g., AndroGel, Testim), patches (Androderm), and other injectable forms (e.g., testosterone cypionate).
• Injectable testosterone formulations represent roughly 20% of TRT market sales due to preference for sustained release and less frequent dosing.

Regulatory Status

• FDA approved Xyosted in August 2019.
• Marketed by Ferring Pharmaceuticals.
• Registration in multiple countries, but primarily US focus.

Market Penetration

• Initial uptake was moderate; growth driven by demand for injectable formulations that maintain serum testosterone levels.
• Prescriber preference favors injections for consistent hormone levels and patient adherence.

Price Overview and Projections

Current Market Pricing

• Average wholesale price (AWP): Approximately USD 200–250 per 10 mL vial.
• Reimbursement rates: Varies by insurer and location; out-of-pocket costs for patients range USD 50–100 per injection, depending on insurance.

Cost Trends and Factors Affecting Price

• Raw material costs and manufacturing expenses influence price stability.
• Competition from other formulations caps price increases.
• Patent status: As a branded product, Xyosted retains exclusivity until at least 2024. Biosimilars or generics could impact pricing thereafter.

Price Projections (2023–2027)

Year	Estimated Price Range (USD per unit)	Notes
2023	200–250	Stable; minor fluctuations due to inflation and supply chain factors
2024	190–245	Potential introduction of bios Comparable to existing levels in late 2024, unless new entrants emerge.
2025	185–240	Slight decline expected, pressure from generics or biosimilars remains low; price stability expected.
2026	180–235	Limited price reductions, driven by market saturation and new formulations.
2027	175–230	Further stabilization; generic alternatives could emerge, applying further downward pressure.

Factors Influencing Price Trends:

• Patent expirations: Loss of exclusivity could lead to price reductions.
• Market penetration: Increased use in outpatient clinics may stabilize pricing.
• Regulatory changes: Government policies on drug pricing and biosimilar adoption could impact costs.
• Manufacturing costs: Fluctuations in raw material prices and supply chain stability impact overall pricing.

Key Market Drivers and Challenges

Drivers

• Increasing prevalence of hypogonadism with aging populations.
• Rising demand for self-administered TRT options, including injectable formulations.
• Physician preference for injectable testosterone for steady serum levels.

Challenges

• Competition from oral and topical alternatives.
• Patent protection expiration prospects.
• Reimbursement pressures from payers limiting growth.

Conclusions

• The market for NDC 46122-0752, Xyosted, remains relatively stable with slight downward pressure anticipated over the next five years.
• Pricing will likely be influenced chiefly by patent status, competition, and reimbursement landscape.
• Growth opportunities depend on expanding indications and increasing acceptance among prescribers and patients.

Key Takeaways

• The current market price is approximately USD 200–250 per vial, with slight declines expected post-2024.
• The market size for TRT is growing at around 4.8% CAGR through 2027.
• Competition from generics and biosimilars is a primary risk affecting future pricing.
• Market growth is driven by an aging population and patient preference for injectable TRT.
• Reimbursement policies and regulatory changes will shape market dynamics.

FAQs

1. How does the price of Xyosted compare to other injectable testosterone therapies?
   Xyosted's price aligns with other branded injectables like testosterone cypionate but may be slightly higher due to formulation differences and delivery system.

2. When are biosimilars or generics expected for Xyosted?
   Likely post-patent expiration, potentially around 2024–2025, which could lead to substantial price reductions.

3. What market segments are most likely to adopt Xyosted?
   Urologists and endocrinologists managing hypogonadism, especially those favoring injectable administration.

4. What regulatory factors could impact future market access?
   Policy changes favoring biosimilar adoption and drug price regulations could reduce market revenue.

5. What are the primary risks for investing in Xyosted's market?
   Entry of lower-priced biosimilars, shifts toward non-injectable TRT options, and reimbursement cuts.

---

References
[1] MarketsandMarkets. (2022). Testosterone replacement therapy market forecast.